左乙拉西坦联合吡仑帕奈对胶质瘤清醒开颅术中癫痫发作的影响
该回顾性队列研究纳入78例接受清醒开颅术中直接电刺激定位的胶质瘤患者,比较单用左乙拉西坦(LEV,50例)与LEV联合吡仑帕奈(PER,28例)预防术中癫痫的效果;联合组术中癫痫发生率为7.1%,显著低于单药组的36.0%(p=0.009),联合组难治性术中癫痫为0%。
要点
- LEV+PER组术中癫痫发生率为7.1%,显著低于LEV单药组的36.0%(p=0.009)。
- 联合组无患者出现难治性术中癫痫(0%)。
- 运动相关区受累、术前癫痫及单用LEV与术中癫痫风险升高相关。
核心结论
- 在胶质瘤清醒开颅术中,LEV+PER治疗与较低的术中癫痫风险显著相关,相比单用LEV更有助于减少术中难治性癫痫。
研究设计与样本
- 回顾性队列研究,纳入78例接受清醒开颅术中直接电刺激定位的连续胶质瘤患者。
- LEV组50例于2017年1月至2019年1月接受单用LEV治疗。
- LEV+PER组28例于2019年3月至2020年1月接受LEV联合PER治疗。
- 术前给予LEV(1000-3000 mg)和/或PER(2-4 mg)。
主要发现
- 术前癫痫(ILAE II-VI级)在LEV组占44%,在LEV+PER组占35.7%,两组差异无统计学意义(p=0.319)。
- 术中癫痫在LEV组发生18例(36.0%),在LEV+PER组发生2例(7.1%)(p=0.009)。
- LEV+PER组难治性术中癫痫为0例(0%)。
- 多因素logistic回归显示术中癫痫与运动相关区受累(HR 6.98,95%CI 1.71-28.56,p=0.007)、术前癫痫(ILAE II-VI级 vs I级,HR 4.44,95%CI 1.22-16.11,p=0.024)及LEV+PER组(HR 0.07,95%CI 0.01-0.44,p=0.005)显著相关。
- 治疗相关不良反应少见且轻微,两组均包括嗜睡、疲倦和头晕。
关键数值与推荐
- 术前用药:LEV 1000-3000 mg和/或PER 2-4 mg。
- 术中癫痫发生率:LEV组36.0%(18例),LEV+PER组7.1%(2例),p=0.009。
- 难治性术中癫痫:LEV+PER组0%。
- 运动相关区受累OR/HR 6.98(95%CI 1.71-28.56,p=0.007)。
- LEV+PER组HR 0.07(95%CI 0.01-0.44,p=0.005)。
临床怎么用
- 对胶质瘤清醒开颅术中癫痫高风险患者,可考虑LEV联合PER方案以降低术中癫痫及难治性癫痫风险。
- 术前应评估运动相关区受累及术前癫痫史以识别术中癫痫高危患者。
- 联合方案不良反应少见且轻微,但仍需关注嗜睡、疲倦和头晕。
局限性
- 为单中心回顾性队列研究,两组用药时段不同,可能存在时间偏倚。
- LEV+PER组样本量较小(28例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the efficacy of levetiracetam (LEV) combined with perampanel (PER) therapy for intraoperative seizure treatment to determine whether a combination of LEV and PER can aid in the prevention of intraoperative intractable seizures during awake surgery. METHODS: The authors performed a retrospective cohort study in 78 consecutive patients with glioma who underwent awake surgery using intraoperative direct electrical stimulation mapping. To prevent intraoperative seizures, 50 patients were treated with the antiepileptic drug LEV only (LEV group) from January 2017 to January 2019, while the remaining 28 patients were treated with LEV plus PER (LEV + PER group) between March 2019 and January 2020. LEV (1000-3000 mg) and/or PER (2-4 mg) were administered before the surgery. RESULTS: Preoperative seizures with International League Against Epilepsy (ILAE) class II-VI occurred in 44% of the patients in the LEV group and in 35.7% of patients in the LEV + PER group, with no significant difference between groups (p = 0.319). Total intraoperative seizures occurred in 18 patients (36.0%) in the LEV therapy group and in 2 patients (7.1%) in the LEV + PER group (p = 0.009). Of these, there were no patients (0%) with intractable seizures in the LEV + PER group. Regarding factors that influence intraoperative seizures in glioma patients during awake brain surgery, multivariate logistic regression models revealed that the occurrence of intraoperative seizures was significantly related to the involvement of motor-related regions (positive vs negative, HR 6.98, 95% CI 1.71-28.56, p = 0.007), preoperative seizure (ILAE class II-VI vs ILAE class I, HR 4.44, 95% CI 1.22-16.11, p = 0.024), and LEV + PER group (positive vs negative, HR 0.07, 95% CI 0.01-0.44, p = 0.005). Treatment-related adverse effects were rare and mild, including sleepiness, tiredness, and dizziness in both treatment groups. CONCLUSIONS: This study demonstrates that LEV + PER therapy is significantly associated with a lower risk of intraoperative seizures compared with LEV therapy alone in patients with glioma during awake brain mapping. These findings will help neurosurgeons conduct safe and reliable awake surgeries and reduce the rate of intraoperative intractable seizures during such procedures.
引用
- Motomura K, Chalise L, Shimizu H, et al. Intraoperative seizure outcome of levetiracetam combined with perampanel therapy in patients with glioma undergoing awake brain surgery. J Neurosurg. 2021. PMID: 33482638. doi:10.3171/2020.8.JNS201400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。